Office of Surveillance and Epidemiology Reorganization Complete

March 12, 2008
BioPharm International Editors

Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, has announced that the reorganization of the Office of Surveillance and Epidemiology (OSE) has been completed.

Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, has announced that the reorganization of the Office of Surveillance and Epidemiology (OSE) has been completed. The OSE now has five divisions:

  • The Division of Risk Management

  • The Division of Medication Error Prevention

  • The Division of Epidemiology

  • The Division of Adverse Event Analysis 1

  • The Division of Adverse Event Analysis 2

Information about leadership and functions for the new configuration can be found on the OSE web site. http://www.fda.gov/cder/Offices/ODS/default.htm

Related Content:

News